Scientific Data. Schedule 2.8(d) of the Company Disclosure Document sets forth a list of all studies involving the use of cell-free DNA in transplantation in which the Company has participated, including the agreements relating to such participation, the party or parties that received and analyzed samples in such study, and whether or not the Company owns or has rights to access and use the samples and data generated in such study.
Appears in 3 contracts
Sources: Merger Agreement (CareDx, Inc.), Merger Agreement (CareDx, Inc.), Merger Agreement (CareDx, Inc.)